NuCana plc · NASDAQ:NCNA
NuCana — Investor Presentation (October 2026)
41 slides from NuCana's investor presentation, October 2026
Slide 1: A New Era in Oncology
A New Era in Oncology Corporate Presentation October 2026 nucana.com
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). A
Slide 3: Harnessing the Power of Phosphoramidate Chemistry
Harnessing the Power of Phosphoramidate Chemistry Transforming Nucleoside Analogs into ProTides
Slide 4: Nucleoside Analogs: Cornerstones of Cancer & Viral Treatments
Nucleoside Analogs Cornerstones of Cancer & Viral Treatments 22 FDA Approved 16 FDA Approved 22 FDA Approved Anti-Cancer Nucleoside Analogs Anti-Viral Nucleoside Anti-Viral Analogs Nucleoside Analogs Including: Including: Inactive & Unprotected Limitations of Nucleoside Analogs Breakdown & Uptake Ac
Slide 5: Transforming Nucleoside Analogs into ProTides
Transforming Nucleoside Analogs into ProTides Nucleoside Analog Inactive & Unprotected Nucleotide Analog ProTide Activated & Protected
Slide 6: ProTides: A New Era In Anti-Virals
ProTides A New Era In Anti-Virals tenofovir alafenamide Hepatitis C HIV & Hepatitis B COVID-19 § Transformed novel nucleoside analog § Transformed nucleoside analog: § Transformed novel nucleoside analog § Highly effective treatment for chronic Viread® (tenofovir disoproxil fumarate) § Treatment for
Slide 7: ProTides: A New Era In Oncology
ProTides A New Era In Oncology § Transformed novel nucleoside analog: 3’-dA § Transformed nucleoside analog: FUDR § Profoundly impacts gene expression in cancer cells § Targeted Thymidylate Synthase Inhibitor § Targets the tumor microenvironment § Induces DNA damage
Slide 8: Current Development Status
Current Development Status INDICATION COMBINATION PRE-CLINICAL PHASE 1 PHASE 2 NuTide:701 Solid Tumors monotherapy Study NuTide:701 Melanoma pembrolizumab Study NuTide:303 Solid Tumors pembrolizumab Study
Slide 9: Multiple Inflection Points in 2026
Multiple Inflection Points in 2026 Cash & Cash Equivalents Cash Runway Important Data Strong cash position provides As of June 30, 2026 runway into 2029 Readouts ~$25.9 million* into 2029 in 2026 & 2027 * Based on exchange rate of £1.00 to $1.33 and reported cash of £19.5 million as of June 30, 2026
Slide 10: Targeted RNA Disruption in Cancer
Targeted RNA Disruption in Cancer
Slide 11: Cordycepin (3'-dA): Compelling Biology, Constrained by Pharmacology
Cordycepin (3’-dA) Compelling Biology, Constrained by Pharmacology For Centuries Post 1950s Development Barrier Biological Potential Pharmacology Blocks Emerges Translation Anti-cancer, metabolic Rapid ADA-mediated breakdown, & immunomodulatory poor cellular uptake & kinase- activities reported depe
Slide 12: Cancer Cells Utilize ATP Differently Compared to Normal Cells
Cancer Cells Utilize ATP Differently Compared to Normal Cells ENERGY ENERGY Balanced ATP production ATP demand increases as supports routine cellular metabolism is reprogrammed functions to fuel tumor growth & survival RNA RNA PROCESSING PROCESSING ATP supports normal mRNA Dysregulated mRNA processi
Slide 13: NUC-7738 Exploits Cancer's ATP Dependency via 3'-dATP Generation
NUC-7738 Exploits Cancer’s ATP Dependency via 3’-dATP Generation Reduced Ribosomal Biogenesis & Protein Synthesis Deprotection Altered Cellular Metabolism (e.g. mitochondrial function) 3’-dAMP 3’-dADP 3’-dATP Disrupts RNA Polyadenylation Altered Alternative Polyadenylation & Gene Expression Enhanced
Slide 14: NUC-7738 Disruption of RNA Processing Leads to Anti-Cancer Effects
NUC-7738 Disruption of RNA Processing Leads to Multiple, Interconnected Anti-Cancer Effects Reduced Ribosomal Biogenesis Altered Cellular Metabolism & Protein Synthesis (e.g. mitochondrial function) Altered processing of ribosomal mRNA Changes in expression & processing & decreased production of pro
Slide 15: NuTide:701 Study Phase 1/2 Design
NuTide:701 Study Phase 1/2 Design (ongoing) Phase 1 Phase 2 Phase 2 Phase 2 Dose Escalation Dose Optimization Dose Optimization Expansion (monotherapy) (monotherapy) (combination) (combination) + + pembrolizumab pembrolizumab completed completed completed ongoing Number of Patients Tumor Type Cutane
Slide 16: Attractive Pharmacokinetic Profile (NUC-7738)
NuTide:701 Study Attractive Pharmacokinetic Profile (NUC-7738) Plasma Intracellular Dose proportional increase in Cmax and AUC NUC-7738 efficiently generates active anti-cancer metabolite (3’-dATP) Long half-life of 3’-dATP (42 hrs) Patients (n=27) dosed at 14 – 900 mg/m 2 Patients (n=3) dosed at 90
Slide 17: Favorable Safety Profile (NUC-7738)
NuTide:701 Study Favorable Safety Profile (NUC-7738) NUC-7738 has been well tolerated § No Grade 4 toxicities § Low rates of Grade 3 toxicities MTD Dose AE occurred 14 28 42 70 112 182 273 400 600 750 900 1350 2000 Total* n=38 (mg/m2) n=2 n=3 n=2 n=3 n=4 n=4 n=5 n=6 n=9 n=5 n=8 n=11 n=2 All Grade Tr
Slide 18: Encouraging Signs of Efficacy (NUC-7738)
NuTide:701 Study Encouraging Signs of Efficacy (NUC-7738) Disease Control Rate: 41% (Efficacy Evaluable Patients) Metastatic Metastatic Metastatic Clival Metastatic Lung Melanoma Melanoma Chordoma Adenocarcinoma 62 years 65 years 72 years 65 years 2 prior lines 1 prior line 1 prior line 2 prior line
Slide 19: Phase 2 Design (NUC-7738 + pembrolizumab)
NuTide:701 Study Phase 2 Design (NUC-7738 + pembrolizumab) Dose Confirmation Cohort (n=12) Objective § Establish RP2D Phase 2 NuTide:701 Study NUC-7738 (1125 mg/m2)* Key endpoints § Safety & tolerability Key Eligibility Criteria Q1W § Anti-tumor activity § Cutaneous melanoma + § PK § Immunotherapy e
Slide 20: Favorable Safety Profile (NUC-7738 + pembrolizumab)
NuTide:701 Study Favorable Safety Profile (NUC-7738 + pembrolizumab) NUC-7738 + pembrolizumab has been well tolerated (n=12) § Low rates of Grade ≥3 toxicities § 1 patient experienced Grade 4 transaminitis (ALT/AST increased) Treatment Related Adverse Events All Grades n(%) Grade 3 n(%) Grade 4 n(%)
Slide 21: Tumor Volume Reductions in PD-1 Inhibitor Resistant Patients
NuTide:701 Study Tumor Volume Reductions in PD-1 Inhibitor Resistant Patients (NUC-7738 + pembrolizumab) § Patient previously refractory to PD-1 inhibitor (nivolumab) + CTLA-4 inhibitor (ipilimumab) had 55% reduction# § Patient with progression on three prior PD-1 therapies (nivolumab x1, pembrolizu
Slide 22: Durable PFS in PD-1 Inhibitor Resistant Patients
NuTide:701 Study Durable PFS in PD-1 Inhibitor Resistant Patients (NUC-7738 + pembrolizumab) PD-1 inhibitor rechallenge typically results in patients progressing at their first scan (2-3 months) * Patient achieved complete metabolic response on PET (no FDG uptake), while CT-based iRECIST assessment
Slide 23: Encouraging Efficacy in PD-1 Inhibitor Resistant Patients
NuTide:701 Study Encouraging Efficacy in PD-1 Inhibitor Resistant Patients (NUC-7738 + pembrolizumab) Case Study 1 Case Study 2 Partial Response in patient with resistance to PD-1 inhibition Evidence of anti-cancer immune response in TME 63 years • 2 target lesions (skin) • BRAF wt 67 years • 2 targ
Slide 24: Encouraging Efficacy: Case Study 3
NuTide:701 Study Encouraging Efficacy in PD-1 Inhibitor Resistant Patients (NUC-7738 + pembrolizumab) Case Study 3 Complete Metabolic Response (PET-based); (PFS 29+ months) 66 years • 2 target lesions (both liver) • BRAF wt Received prior PD-1 inhibitor containing regimen NUC-7738 + pembrolizumab Ti
Slide 25: Increases Antigen Presentation & T-cell Activation in Patient Biopsies
Increases Antigen Presentation & T-cell Activation in Patient Biopsies Heatmaps illustrating RNA expression reveal a relative Lymphocytes (light blue green) increase in mRNA levels of genes associated with attaching to cancer cells (yellow) antigen transport & presentation and T-cell activation from
Slide 26: NuTide:723 Planned First Line Phase 1b Study
NuTide:723 Study Planned First Line Phase 1b Study (NUC-7738 + Opdualag) First Line Melanoma NUC-7738 Opdualag (750 mg/m2) + (480/160 mg) Q1W Q4W NuTide:723 NUC-7738 Opdualag Proposed Study (1000 mg/m2) + (480/160 mg) Phase 1b Adaptive BOIN Design Key Eligibility Criteria Q1W Q4W § Stage III & IV cu
Slide 27: Melanoma Market Opportunity
Melanoma Market Opportunity $12.9 billion Estimated sales in 8 major markets in 20301 331,722 new cases in 2022 112,000 people diagnosed actual2 in the US with invasive 510,000 new cases in 2040 melanoma in 2026 projected4 projected3 58,667 deaths in 2022 actual2 5-year survival rate: 30% Stage IV m
Slide 28: Multiple Development Opportunities for NUC-7738
Multiple Development Opportunities for NUC-7738 Small Cell Lung Cancer Head & Neck Cancer Extensive stage disease Unresectable/metastatic (including untreated, PD-L1 (including PD-(L)1 resistant, resistant, chemo-ineligible) chemo-ineligible) Non-Small Cell Lung Cancer Breast Cancer (triple-negative
Slide 29: Targeted Thymidylate Synthase Inhibitor
Targeted Thymidylate Synthase Inhibitor
Slide 30: Thymidylate Synthase: An Important Target for Anti-Cancer Therapies
Thymidylate Synthase An Important Target for Anti-Cancer Therapies TS inhibitors are widely used despite their insufficient inhibition of the target enzyme Thymidylate Synthase (TS) is a critical enzyme for nucleotide synthesis § Converts uridine (dUMP) to thymidine (dTMP) § Essential for DNA replic
Slide 31: NUC-3373 Induces DNA Damage & Potentiates an Immune Response
NUC-3373 Induces DNA Damage & Potentiates an Immune Response Bré et al (2023) Cancer Chemother Pharmacol: 91(5): 401-412; Read et al (2025) PLoS One: 16; 20(9): e0331567
Slide 32: NUC-3373 Clinical Studies
NUC-3373 Clinical Studies Over 300 patients have received NUC-3373 across the clinical program STUDY COMBINATION POPULATION PATIENTS NuTide:301 monotherapy Solid Tumors 59 Phase 1 (end-stage) NuTide:302 leucovorin (LV) CRC 38 Phase 1b (end-stage) NuTide:302 LV + irinotecan CRC 32 Phase 1b (end-stage
Slide 33: NuTide:323 Study Key Learnings Inform the Path Forward
NuTide:323 Study Key Learnings Inform the Path Forward for NUC-3373 Stopped early in 2024 after planned review NUC-3373 Is differentiated from 5-FU • A pre-planned initial analysis indicated NUFIRI + bevacizumab was • NUC-3373 generates higher FdUMP levels, driving more potent unlikely to achieve su
Slide 34: NuTide:303 Phase 1b Study Design
NuTide:303 Study Phase 1b Study (NUC-3373 + pembrolizumab or NUC-3373 + docetaxel) NuTide:303 Module 1 Study NUC-3373 Key Eligibility Criteria (1875 mg/m2 ) § Advanced solid tumors Q1W + § Progressed on ≤2 prior lines, pembrolizumab Objective may include PD-(L)1 inhibitor (200 mg/m2) § ECOG PS 0-1 Q
Slide 35: Favorable Safety Profile (NUC-3373 + pembrolizumab)
NuTide:303 Study Favorable Safety Profile (NUC-3373 + pembrolizumab) NUC-3373 + pembrolizumab has been well tolerated (n=13) § No Grade 4 toxicities Treatment Related Adverse Events All Grades n(%) Grade 3 n(%) Grade 4 n(%) Vomiting 10 (77) 0 0 Nausea 9 (69) 0 0 Diarrhea 6 (46) 0 0 Fatigue 6 (46) 0
Slide 36: Prolonged Time on Treatment (NUC-3373 + pembrolizumab)
NuTide:303 Study Prolonged Time on Treatment (NUC-3373 + pembrolizumab) Encouraging duration of clinical benefit in PD-(L)1 experienced patients * Data presented as per end of study cut-off date (30 May 2025). This patient was progression-free as of 31 August 2025 (22 months ongoing) & continued to
Slide 37: NuTide:303 Encouraging Signs of Efficacy
NuTide:303 Study Encouraging Signs of Efficacy NUC-3373 + pembrolizumab NUC-3373 + docetaxel Cutaneous Bladder Pleural NSCLC Melanoma Cancer Mesothelioma (squamous) 75 years 72 years 60 years 77 years • BRAF mt • Lynch Syndrome 3 prior lines 2 prior lines 2 prior lines 2 prior lines 1) pembrolizumab
Slide 38: Strong Intellectual Property Position
Strong Intellectual Property Position Worldwide exclusive rights for all programs: 284 granted patents and 61 pending applications* KEY PATENTS STATUS EXPIRATION+ TERRITORIES (excluding any extensions) 100 granted, 42 pending, including: Composition of matter Granted (US, EP, CN, JP) 2035 + others F
Slide 39: Key Expected Milestones: 2026
Key Expected Milestones: 2026 INDICATION COMBINATION PHASE MILESTONE Complete Recruitment NuTide:701 Melanoma pembrolizumab Phase 2 Announce Expansion Data Study Obtain FDA Feedback on Registration Strategy NuTide:303 Solid Tumors pembrolizumab Phase 1b/2 Announce Development Plan Study
Slide 40: Investment Highlights
Investment Highlights Targeted RNA Disruption in Cancer Targeted TS inhibitor Encouraging signs of efficacy Induces DNA damage Potentiates immune checkpoint blockade Encouraging signs of efficacy Favorable safety profile Favorable safety profile : NCNA Experienced Team Improving Survival Accomplishe
Slide 41: nucana.com
NCNA | Nasdaq) NUSe ANEW ERA IN ON OGy porasaaq ~NCNA NUCANA nucana.com